Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Clinical trial NCT03202316 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03202316
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Breast Inflammatory Carcinoma Stage IV Breast Inflammatory Carcinoma

Start date: 2017-08-11
Primary completion: 2027-12-31
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.